<DOC>
	<DOCNO>NCT00005844</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness oxaliplatin treat child advance solid tumor .</brief_summary>
	<brief_title>Oxaliplatin Treating Children With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose oxaliplatin child advance solid tumor . - Determine toxic effect drug patient . - Determine safety drug patient . - Determine pharmacokinetics drug patient . - Assess relationship pharmacokinetic parameter toxicity regimen response patient . - Determine anti-tumor effect drug patient . OUTLINE : This dose-escalation study . Patients receive oxaliplatin IV 2 hour day 1 ( every 3 week 6 course ) OR day 1 , 14 , 28 ( every 6 week 3 course ) . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD dose level 1-4 determine , additional cohort 3-6 patient accrue treated oxaliplatin every 2 week ( 9 dos ) . PROJECTED ACCRUAL : Approximately 6-20 patient accrue study within 1-3.3 year .</detailed_description>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic unresectable solid tumor amenable standard treatment Histological confirmation require brain stem tumors No known brain metastases No leukemia PATIENT CHARACTERISTICS : Age : 21 Performance status : ECOG 02 OR Lansky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm^3 ( except marrow involvement ) Hemoglobin least 8 g/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin 0.21.4 mg/dL AST/ALT great 3 time upper limit normal Renal : Creatinine normal age OR Creatinine clearance least 50 mL/min Electrolytes , calcium , phosphorus normal Cardiovascular : No symptomatic congestive heart failure , unstable angina , cardiac arrhythmia Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No active graftvshost disease ( GVHD ) No allergy platinum compound antiemetic No uncontrolled concurrent illness infection No evidence neuropathy Blood sugar normal PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior hematopoietic growth factor At least 3 month since prior stem cell transplantation recover Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosourea ) Endocrine therapy : Not specify Radiotherapy : At least 6 week since prior extensive radiotherapy significant marrowcontaining compartment At least 6 month since prior craniospinal radiotherapy ; total abdominal , pelvic , extensive lung radiotherapy ; mantle Yport radiotherapy At least 6 month since prior total body irradiation Surgery : Not specify Other : No concurrent therapy GVHD No concurrent anticancer investigational commercial agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>